Javascript Disabled

This site requires Javascript in order to function properly. Please enable it in your browser's settings.

Portrazza logo

A treatment option for squamous lung cancer

Ask your healthcare team if Portrazza is right for you

Scroll down to learn more

Scroll Down to View More Arrow

It's important to know you're not alone as you begin your treatment journey. Through Lilly PatientOne, you and your doctor have a partner in finding potential solutions in the complex and often confusing world of coverage and reimbursement. Lilly PatientOne offers a range of services for your individual situation, even if you're not insured. So you can start treatment with one less worry. Learn how Lilly PatientOne may be able to help eligible patients who have been prescribed Portrazza.

Order educational resources to help you manage treatment

As you begin—or continue—Portrazza treatment, you may want more information to keep at home. Below you'll find a treatment guide and Self-Care Kit that you can have shipped directly to you at no cost. Remember, your doctor and healthcare team are the best sources for information about your treatment, so please be sure to discuss any questions you may have about your treatment or these materials with them.

A Self-Care Kit: helping you take care of your skin and nails
The Self-Care Kit contains information on the possible skin and nail side effects of Portrazza, as well as products and suggestions to help manage these changes. This kit includes:
  • A brochure with information about potential skin and nail changes and helpful tips
  • Lotions, sunscreen, gentle bathing products, and a nail kit
Self-Care Kit
Self-Care Kit
Portrazza Treatment Guide
This brochure provides an overview of Portrazza treatment, including:
  • What Portrazza is used for
  • What you can expect during treatment
  • Important Safety Information for Portrazza
  • Additional patient resources
Portrazza Treatment Guide
Portrazza Treatment Guide

Lilly Oncology: More than Medicine

When life becomes life with cancer, it's not only about fighting the disease. It's a journey with ever-changing emotional and practical needs that go beyond treatment. Lilly Oncology has made a deep commitment to understanding that journey, and is determined to find ways to help meet those needs—for those whose lives are changed because of cancer.

YOUR LUNG CANCER JOURNEY

Lung cancer is the most common cancer in the world. In the United States alone, it accounted for about 13% of all new cancer diagnoses in 2015. Lung cancer affects the cells or tissues of the lungs and can spread to other parts of the body.

Understand how lung cancer is diagnosed and treated—and what you might expect along the way

SUPPORT FOR YOUR LUNG CANCER JOURNEY

Lilly Oncology is grateful to work with leading patient advocacy and medical organizations to help raise awareness about cancer, educate the public, support cancer research, and influence change in public policy. Above all, Lilly Oncology is determined to support those who face cancer every day—those who are fighting the disease and those who care for them.

Below is a list of websites that will provide you with more information about lung cancer, living with cancer, and patient and family support groups:

  • Lung cancer support groups
  • Lung cancer support groups
  • Lung cancer support groups
  • Lung cancer support groups

Lung Cancer Alliance

Lung Cancer Alliance® is a nonprofit organization solely dedicated to saving lives and advancing research by empowering those living with and at risk for lung cancer. They offer personalized, professional support, advocate for increased lung cancer research funding, and conduct nationwide education campaigns.

This information has been provided by the listed organizations, and Lilly is not responsible for the content. Its use on this site is not intended to serve as an endorsement of the listed organizations. All third-party names, logos, brands, and other trademarks are the property of their respective trademark owners. Those trademark owners are not affiliated with Lilly and they do not sponsor or endorse this website.

Learn more about additional cancer and lung cancer support groups

Lung cancer support groups

The American Lung Association® is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research. The Lung Association is committed to defeating lung cancer and supporting those affected by it. Through our strategic cause initiative, LUNG FORCE, we have three priorities: 1) Make lung cancer a cause that people care about – and act on; 2) Educate and empower patients and healthcare providers; and 3) Raise critical funds for lung cancer research.

This information has been provided by the listed organizations, and Lilly is not responsible for the content. Its use on this site is not intended to serve as an endorsement of the listed organizations. All third-party names, logos, brands, and other trademarks are the property of their respective trademark owners. Those trademark owners are not affiliated with Lilly and they do not sponsor or endorse this website.

Learn more about additional cancer and lung cancer support groups

Lungevity

LUNGevity Foundation® is focused on changing outcomes for people living with lung cancer through research, education, and support. LUNGevity strategically funds a robust portfolio of translational research to find lung cancer early and treat it more effectively. The organization also provides a community of empowerment, support, and hope for everyone affected by lung cancer through their extensive educational resources, online peer-to-peer support, and in-person survivorship programs.

This information has been provided by the listed organizations, and Lilly is not responsible for the content. Its use on this site is not intended to serve as an endorsement of the listed organizations. All third-party names, logos, brands, and other trademarks are the property of their respective trademark owners. Those trademark owners are not affiliated with Lilly and they do not sponsor or endorse this website.

Learn more about additional cancer and lung cancer support groups

Lung Cancer Foundation

The Bonnie J. Addario Lung Cancer Foundation is a nonprofit organization that actively works with physicians, organizations, and people affected by lung cancer. To reach our goal of making lung cancer a chronically managed disease by 2023, we empower and educate patients via patient services and programs, work with physicians via our Community Hospital Center of Excellence program, fund cutting-edge research, build strategic collaborations, and raise public awareness.

This information has been provided by the listed organizations, and Lilly is not responsible for the content. Its use on this site is not intended to serve as an endorsement of the listed organizations. All third-party names, logos, brands, and other trademarks are the property of their respective trademark owners. Those trademark owners are not affiliated with Lilly and they do not sponsor or endorse this website.

Learn more about additional cancer and lung cancer support groups

CREATIVE OUTLETS FOR YOUR LUNG CANCER JOURNEY
Creative Outlets

When cancer becomes part of your life, so does stress, anxiety, and fear. But many people have found an outlet through art—whether it’s painting, music, dance, or poetry. If you’re a person with cancer, or the friend, loved one, or caregiver of someone who has cancer, expressing your feelings through creativity may help you manage the physical and emotional stress associated with a cancer diagnosis.

Creative Outlets

In fact, the impact of creative expression on people touched by cancer is just now being fully appreciated. In 2013, the Journal of the American Medical Association Internal Medicine published a review of 27 studies of more than 1500 people living with cancer and concluded art therapy has the potential to impact symptoms of pain, anxiety, and depression and overall quality of life.

Creative Outlets

Even if you’ve never been involved in the arts before, you might find that expressing yourself creatively gives you a sense of freedom and inspiration. If you’re interested, ask your care team about art, music, dance, or other creative therapy programs available in your area, or look for programs online.

With our commitment to discovering new ways of caring beyond treatment, Lilly Oncology offers an art program with the goal of giving those affected by cancer an outlet to share their cancer journey through creative expression.

Learn more, including how to participate

Ask Us
A Question
Lilly Logo, Ask Us a Question
By calling this number, you’ll have access to a healthcare professional who can provide additional information similar to what you can find on this website. The toll-free number is a service provided by Eli Lilly and Company and is not intended to replace the advice of your healthcare team. If you have a medical emergency, you should immediately call 911 (or your local emergency services number). If you are seeking medical advice, you should direct those questions to your healthcare team. Your own healthcare team is the best source of information regarding your health.
View All

Portrazza™ (necitumumab) is a prescription medicine used with a combination of 2 chemotherapy drugs (gemcitabine and cisplatin) for the initial treatment of a type of lung cancer called squamous non-small cell lung cancer (NSCLC) that has spread (metastasized).

Limitation of Use: Portrazza is not for use to treat a different type of cancer called nonsquamous NSCLC.

WARNING: CARDIAC ARREST AND LOW MAGNESIUM IN THE BLOOD

Cardiac arrest and/or sudden death occurred in 3% of patients treated with Portrazza plus gemcitabine and cisplatin in a clinical trial. Most of these patients had other health problems, like a history of heart disease, low magnesium in their blood, a lung problem called chronic obstructive pulmonary disease (COPD), and/or high blood pressure. The risk of cardiac arrest or sudden death in patients with these health problems is not known. Your healthcare provider will do blood tests to check your magnesium, potassium, and calcium during and after your Portrazza treatment. You may receive treatment for low levels of these in your blood. Take medicines to replace electrolytes exactly as prescribed by your physician.

Low magnesium in the blood occurred in 83% of patients treated with Portrazza. It was severe in 20% of patients.

Before beginning treatment, you should discuss the potential benefits and risks of Portrazza with your doctor. Some side effects of Portrazza can be serious and may include:

Blood Clots

  • Blood clots in the veins occurred in 9% of people and blood clots in the arteries occurred in 5% of people who took Portrazza plus gemcitabine and cisplatin in a clinical trial; some of these caused people to die.
  • The risk of blood clots may be higher if you have already had a blood clot in the past.
  • Your doctor will observe you and stop your treatment if you develop a serious or life-threatening blood clot.

Skin Reactions

  • Skin reactions occurred in 79% of the people who took Portrazza in a clinical trial. Skin reactions were severe in 8% of people. These reactions ranged from a rash, a rash that looked like acne, itchy or dry skin, cracks in the skin, red and swollen skin, and/or a skin infection around fingernails or toenails.
  • Reactions usually began during the first 2 weeks of treatment and got better about 4 months after they started.
  • If you have a skin reaction, your doctor may change your dose of Portrazza.
  • If your reactions are serious enough, your treatment may need to be stopped right away and not started again.
  • Time in the sun may worsen skin reactions; limit sun exposure with protective clothing and use sunscreen.

Allergic Reactions

  • Portrazza can cause allergic reactions in some people when going through the vein. This occurred in 1.5% of the people who were given Portrazza plus gemcitabine and cisplatin in a clinical trial, and was severe in 0.4%. Most of these allergic reactions happened during the first or second dose of Portrazza.
  • Symptoms can include trouble breathing, wheezing, fever, and chills.
  • A member of your healthcare team will give you the infusion and watch for signs of allergic reactions. They may give you medicine before giving you Portrazza to help prevent these reactions. Or they may give you Portrazza more slowly.
  • If your reactions are serious or life threatening, your treatment may need to be stopped right away and not started again.

Harmful Effects if Used for a Different Type of Lung Cancer

  • Portrazza is not for use in patients who have a type of lung cancer that is different than yours (called nonsquamous non-small cell lung cancer).
  • Serious and fatal side effects have happened in people who took Portrazza with a different chemotherapy combination (pemetrexed and cisplatin) for this type of lung cancer.

Harmful Effects to Unborn Babies

  • Portrazza can harm your unborn baby. You should avoid getting pregnant and use adequate contraception (birth control) while receiving Portrazza and for at least 3 months after stopping Portrazza.

What are the most common side effects of Portrazza?

The most common side effects in patients treated with Portrazza were:

  • Low levels of magnesium (83%) and/or other electrolytes (calcium, potassium, and phosphate) in the blood
  • Rash (44%)
  • Vomiting (29%)
  • Diarrhea (16%)
  • Acne-like rash (15%)

The most common severe side effects in patients treated with Portrazza were:

  • Low levels of magnesium (20%) and/or other electrolytes (calcium, potassium, and phosphate) in the blood
  • Blood clots (5%)
  • Rash (4%)
  • Vomiting (3%)

These are not all of the possible side effects with Portrazza. Tell your doctor about any side effect you have and/or any change in the way you feel. For more information, ask a member of your healthcare team.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/medwatch or call 1-800-FDA-1088.

What should I tell my doctor before taking Portrazza?

Tell your doctor about all of your health conditions, including if you:

  • Have a history of heart problems
  • Have a history of high blood pressure
  • Have a history of lung problems (COPD)
  • Have had or are at high risk for blood clots
  • Are pregnant or may become pregnant, as Portrazza may harm your unborn baby. You should avoid getting pregnant and use adequate contraception (birth control) while receiving Portrazza and for at least 3 months after stopping Portrazza.
  • Are breastfeeding. You should not breastfeed while receiving Portrazza and for at least 3 months after stopping Portrazza.

Tell your doctor about all the medications you are taking, including prescription and over-the-counter medications, herbal remedies, and vitamin supplements.

How is Portrazza given?

  • Portrazza is given by a process called an intravenous (IV) infusion (through a vein).
  • When you begin taking Portrazza, you will take it with 2 chemotherapy (cancer) drugs called gemcitabine and cisplatin. During each visit, Portrazza will be given first, and this will typically take about 1 hour. The other 2 chemotherapy drugs will be given after Portrazza.
  • One cycle of treatment takes 21 days and infusions are given on day 1 and day 8, which can continue for up to 6 cycles, or about 18 weeks as long as your treatment is working and you are able to tolerate it.
  • If the treatment is still working and you are able to tolerate it, you may continue to receive Portrazza without chemotherapy on days 1 and 8 of each 21-day cycle for as long as your doctor recommends.
  • Your doctor may also give you other medication(s) before your Portrazza infusion to help manage possible side effects.

Portrazza is available by prescription only.

Please see full Prescribing Information for additional information about Portrazza, including Boxed Warnings for cardiac arrest and low magnesium in the blood.

NE DTC ISI 25NOV2015

 
 

What is Portrazza used for?

Portrazza™ (necitumumab) is a prescription medicine used with a combination of 2 chemotherapy drugs (gemcitabine and cisplatin) for the initial treatment of a type of lung cancer called squamous non-small cell lung cancer (NSCLC) that has spread (metastasized).

Limitation of Use: Portrazza is not for use to treat a different type of cancer called nonsquamous NSCLC.

Important Safety Information for Portrazza

What is the most important information I should know about Portrazza?

WARNING: CARDIAC ARREST AND LOW MAGNESIUM IN THE BLOOD

Cardiac arrest and/or sudden death occurred in 3% of patients treated with Portrazza plus gemcitabine and cisplatin in a clinical trial. Most of these patients had other health problems, like a history of heart disease, low magnesium in their blood, a lung problem called chronic obstructive pulmonary disease (COPD), and/or high blood pressure. The risk of cardiac arrest or sudden death in patients with these health problems is not known. Your healthcare provider will do blood tests to check your magnesium, potassium, and calcium during and after your Portrazza treatment. You may receive treatment for low levels of these in your blood. Take medicines to replace electrolytes exactly as prescribed by your physician.

Low magnesium in the blood occurred in 83% of patients treated with Portrazza. It was severe in 20% of patients.

Before beginning treatment, you should discuss the potential benefits and risks of Portrazza with your doctor. Some side effects of Portrazza can be serious and may include:

Blood Clots

  • Blood clots in the veins occurred in 9% of people and blood clots in the arteries occurred in 5% of people who took Portrazza plus gemcitabine and cisplatin in a clinical trial; some of these caused people to die.
  • The risk of blood clots may be higher if you have already had a blood clot in the past.
  • Your doctor will observe you and stop your treatment if you develop a serious or life-threatening blood clot.

Skin Reactions

  • Skin reactions occurred in 79% of the people who took Portrazza in a clinical trial. Skin reactions were severe in 8% of people. These reactions ranged from a rash, a rash that looked like acne, itchy or dry skin, cracks in the skin, red and swollen skin, and/or a skin infection around fingernails or toenails.
  • Reactions usually began during the first 2 weeks of treatment and got better about 4 months after they started.
  • If you have a skin reaction, your doctor may change your dose of Portrazza.
  • If your reactions are serious enough, your treatment may need to be stopped right away and not started again.
  • Time in the sun may worsen skin reactions; limit sun exposure with protective clothing and use sunscreen.

Allergic Reactions

  • Portrazza can cause allergic reactions in some people when going through the vein. This occurred in 1.5% of the people who were given Portrazza plus gemcitabine and cisplatin in a clinical trial, and was severe in 0.4%. Most of these allergic reactions happened during the first or second dose of Portrazza.
  • Symptoms can include trouble breathing, wheezing, fever, and chills.
  • A member of your healthcare team will give you the infusion and watch for signs of allergic reactions. They may give you medicine before giving you Portrazza to help prevent these reactions. Or they may give you Portrazza more slowly.
  • If your reactions are serious or life threatening, your treatment may need to be stopped right away and not started again.

Harmful Effects if Used for a Different Type of Lung Cancer

  • Portrazza is not for use in patients who have a type of lung cancer that is different than yours (called nonsquamous non-small cell lung cancer).
  • Serious and fatal side effects have happened in people who took Portrazza with a different chemotherapy combination (pemetrexed and cisplatin) for this type of lung cancer.

Harmful Effects to Unborn Babies

  • Portrazza can harm your unborn baby. You should avoid getting pregnant and use adequate contraception (birth control) while receiving Portrazza and for at least 3 months after stopping Portrazza.

What are the most common side effects of Portrazza?

The most common side effects in patients treated with Portrazza were:

  • Low levels of magnesium (83%) and/or other electrolytes (calcium, potassium, and phosphate) in the blood
  • Rash (44%)
  • Vomiting (29%)
  • Diarrhea (16%)
  • Acne-like rash (15%)

The most common severe side effects in patients treated with Portrazza were:

  • Low levels of magnesium (20%) and/or other electrolytes (calcium, potassium, and phosphate) in the blood
  • Blood clots (5%)
  • Rash (4%)
  • Vomiting (3%)

These are not all of the possible side effects with Portrazza. Tell your doctor about any side effect you have and/or any change in the way you feel. For more information, ask a member of your healthcare team.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/medwatch or call 1-800-FDA-1088.

What should I tell my doctor before taking Portrazza?

Tell your doctor about all of your health conditions, including if you:

  • Have a history of heart problems
  • Have a history of high blood pressure
  • Have a history of lung problems (COPD)
  • Have had or are at high risk for blood clots
  • Are pregnant or may become pregnant, as Portrazza may harm your unborn baby. You should avoid getting pregnant and use adequate contraception (birth control) while receiving Portrazza and for at least 3 months after stopping Portrazza.
  • Are breastfeeding. You should not breastfeed while receiving Portrazza and for at least 3 months after stopping Portrazza.

Tell your doctor about all the medications you are taking, including prescription and over-the-counter medications, herbal remedies, and vitamin supplements.

How is Portrazza given?

  • Portrazza is given by a process called an intravenous (IV) infusion (through a vein).
  • When you begin taking Portrazza, you will take it with 2 chemotherapy (cancer) drugs called gemcitabine and cisplatin. During each visit, Portrazza will be given first, and this will typically take about 1 hour. The other 2 chemotherapy drugs will be given after Portrazza.
  • One cycle of treatment takes 21 days and infusions are given on day 1 and day 8, which can continue for up to 6 cycles, or about 18 weeks as long as your treatment is working and you are able to tolerate it.
  • If the treatment is still working and you are able to tolerate it, you may continue to receive Portrazza without chemotherapy on days 1 and 8 of each 21-day cycle for as long as your doctor recommends.
  • Your doctor may also give you other medication(s) before your Portrazza infusion to help manage possible side effects.

Portrazza is available by prescription only.

Please see full Prescribing Information for additional information about Portrazza, including Boxed Warnings for cardiac arrest and low magnesium in the blood.

NE DTC ISI 25NOV2015